HomeFilePharmacology

Pharmacology

View Category

Antiplatelet

TCT 2021 | STOPDAPT-2 and MASTER-DAPT: The Conversation Continues from ESC to TCT

Research on short-term dual antiplatelet therapy (DAPT) is still controversial. These discussions, however, seem to lead to...
solaci -
Learn More
Antithrombotic Anticoagulants

Atrial Fibrillation and Dementia: Which Anticoagulant Agent Presents the Lowest Risk?

Atrial fibrillation is a risk factor for dementia and anticoagulant agents have been proven to decrease it....
solaci -
Learn More
Antithrombotic Anticoagulants

AFIRE Trial: Atrial Fibrillation and PCI. What is the Ideal Therapy?

Patients with atrial fibrillation undergoing percutaneous coronary intervention (PCI) will benefit from rivaroxaban monotherapy both in terms...
solaci -
Learn More
Antithrombotic Anticoagulants

Are Antithrombotics Necessary in Outpatients after COVID-19?

According to this recent study (soon to be published in JAMA), antithrombotic therapy has no clinical benefits...
solaci -
Learn More
Other

Hypertensive Patients: Maximizing Doses or Adding New Drugs

Adding new medication in moderate doses to control hypertension conveniently maximizes efficacy, reduces adverse effects and minimizes...
solaci -
Learn More
Acute coronary syndromes

STOPDAPT-2 ACS: One-Month DAPT NOT Enough in acute patients

One-month dual antiplatelet therapy (DAPT) in patients undergoing acute coronary syndrome (ACS) did not reach the safety...
solaci -
Learn More
Antithrombotic Anticoagulants

TAVR and Anticoagulation: Direct Anticoagulant Agents or Vitamin K Inhibitors?

In some patients, using an anticoagulant agent is not an option, it is just prescribed. Based on...
solaci -
Learn More
Antiplatelet

XIENCE SHORT DAPT | Ideal DAPT Period for Patients at High Risk of Bleeding

In patients at high risk of bleeding undergoing coronary stenting with a Xience stent, 1-to-3-month DAPT period...
solaci -
Learn More